CSIIのチャート
CSIIの企業情報
| symbol | CSII |
|---|---|
| 会社名 | Cardiovascular Systems Inc （カ―ディオバスキュラ―・システムズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 カーディオバスキュラー・システムズ(Cardiovascular Systems Inc.)は、医療技術会社であり、動脈カルシウムを含む末梢・冠動脈疾患に罹患する患者の治療に従事する。同社は、末梢・冠状動脈の両方の商用アプリケーションに、軌道アテローム切除技術を開発する。末梢動脈疾患（PAD）システムは、膝の上下の脚動脈におけるプラークタイプを治療できるカテーテルベースのプラットフォームである。同社の主力製品には、「Diamondback 360 Peripheral Orbital Atherectomy System」(OAS) (Diamondback 360 Peripheral)、「Stealth 360 OAS」(Stealth 360)、「Diamondback 360 Peripheral」、「Diamondback 360 60cm Peripheral」、「Diamondback 360 Low Profile Peripheral」、「Diamondback 360 1.50 Peripheral」及び「Diamondback 360 2.00 Peripheral」がある。同社の冠状動脈疾患（CAD）製品である「Diamondback 360 Coronary OAS」（Coronary OAS）は、重度石灰化冠状動脈の治療薬として販売される。 カ―ディオバスキュラ―・システムズは、米国の医療機器メ―カ―。血管疾患のためのインタ―ベンション治療システムの開発と商業化に焦点を当てる。末梢動脈疾患の製品、ステルス360パッドシステム、ダイヤ360パッドシステム、およびプレデタ―360パッドシステムは、カテ―テルベ―スのプラットフォ―ムで、脚の石灰化冠状動脈の治療法として使用される。 Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company's orbital atherectomy system treats calcified and fibrotic plaque in arterial vessels throughout the leg and heart and addresses many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. |
| 本社所在地 | 1225 Old Highway 8 Northwest St. Paul MN 55112-6416 USA |
| 代表者氏名 | Scott R. Ward スコットR.ワード |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 651-259-1600 |
| 設立年月日 | 2000年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1981年 |
| 従業員数 | 652人 |
| url | www.csi360.com |
| nasdaq_url | https://www.nasdaq.com/symbol/csii |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 5.96400 |
| 終値（lastsale） | 36.45 |
| 時価総額（marketcap） | 1265033663.55 |
| 時価総額 | 時価総額（百万ドル） 1262.951 |
| 売上高 | 売上高（百万ドル） 217.04300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1167.211 |
| 当期純利益 | 当期純利益（百万ドル） 1.71200 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Cardiovascular Systems Inc revenues increased 6% to $217M. Net income totaled $1.7M vs. loss of $1.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Stock-based Compensation in R&D decrease of 4% to $967K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.06 to $0.05. |
CSIIのテクニカル分析
CSIIのニュース
Cardiovascular Systems, Inc. 2023 Q1 - Results - Earnings Call Presentation (NASDAQ:CSII) 2022/11/16 19:14:07 Seeking Alpha
The following slide deck was published by Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc. (CSII) Q1 2023 Earnings Call Transcript 2022/11/05 17:58:03 Seeking Alpha
Cardiovascular Systems, Inc. (NASDAQ:NASDAQ:CSII) Q1 2023 Results Conference Call November 03, 2022 09:00 AM ET Company Participants Jack Nielsen - Vice President of Investor Relations…
Cardiovascular Systems GAAP EPS of -$0.27 misses by $0.04, revenue of $59.67M beats by $0.33M 2022/11/03 11:14:32 Seeking Alpha
Cardiovascular Systems press release (CSII): Q1 GAAP EPS of -$0.27 misses by $0.04.Revenue of $59.67M (+2.2% Y/Y) beats by $0.33M.Fiscal Year 2023 Guidance:Ward added, “Q1 results…
Cardiovascular Systems, Inc. Reports Fiscal 2023 First Quarter Financial Results 2022/11/03 11:00:00 Wallstreet:Online
Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its first quarter, ended September 30, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO “We are pleased with the state of
Cardiovascular Systems Q1 2023 Earnings Preview 2022/11/02 16:09:44 Seeking Alpha
Cardiovascular Systems (CSII) is scheduled to announce Q1 earnings results on Thursday, November 3rd, before market open.The consensus EPS Estimate is -$0.23 and the consensus Revenue…
Cardiovascular Systems, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:CSII) 2022/05/05 07:02:01 Seeking Alpha
The following slide deck was published by Cardiovascular Systems, Inc.
Cardiovascular Systems (CSII) Q3 2022 Earnings Call Transcript 2022/05/04 20:00:53 The Motley Fool
CSII earnings call for the period ending March 31, 2022.
Cardiovascular Systems GAAP EPS of -$0.25 beats by $0.03, revenue of $56.22M misses by $1.16M 2022/05/04 11:10:37 Seeking Alpha
Cardiovascular Systems press release (CSII): FQ3 GAAP EPS of -$0.25 beats by $0.03.Revenue of $56.22M (-11.1% Y/Y) misses by $1.16M.As of March 31, 2022, CSI had cash and…
Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results 2022/05/04 11:00:00 Business Wire
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its third quarter, ended March 31, 2022. Executive Commentary – Scott Ward, Chairman, President and CEO “Third quarter results were in line with our expectations. Despite the impact that Omicron had on hospital capacit
Cardiovascular Systems Q3 2022 Earnings Preview (NASDAQ:CSII) 2022/05/03 16:34:04 Seeking Alpha
Cardiovascular Systems (CSII) is scheduled to announce Q3 earnings results on Wednesday, May 4th, before market open.The consensus EPS Estimate is -$0.33 (vs
Peripheral Vascular Devices Market is Estimated to Surpass USD 13 Billion by 2026 2022/02/22 18:00:00 Benzinga
New York, USA, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Peripheral Vascular Devices Market is Estimated to Surpass USD 13 Billion by 2026 As per DelveInsight analysis, the demand for Peripheral Vascular Devices is increasing due to the rapid rise in cardiovascular and peripheral vascular diseases prevalence, as well as the approval of new and improved products by market players along with the rising frequency of lifestyle disorders such as diabetes and hypertension. DelveInsight''s Peripheral Vascular Devices Market Insights report provides the current and forecast Peripheral Vascular Devices market, upcoming device innovation, individual market shares, challenges, drivers, barriers, and market trends and key Peripheral Vascular Device companies in the market. Key Takeaways from the Peripheral Vascular Devices Market report According to DelveInsight analysis, North America is expected to dominate the Peripheral Vascular Devices market during the forecast period. Key Peripheral Vascular Device companies working in the global market are Medtronic, Boston Scientific Corporation, B.
Cardiovascular Systems (CSII) Q2 2022 Earnings Call Transcript 2022/02/04 02:00:26 The Motley Fool
CSII earnings call for the period ending December 31, 2021.
Cardiovascular Systems, Inc. (CSII) CEO Scott Ward on Q2 2022 Results - Earnings Call Transcript 2022/02/03 19:23:06 Seeking Alpha
Cardiovascular Systems, Inc. 2022 Q2 - Results - Earnings Call Presentation 2022/02/03 18:21:47 Seeking Alpha
Cardiovascular Systems GAAP EPS of -$0.23 misses by $0.09, revenue of $59.1M misses by $3.56M, cuts FY fuidance 2022/02/03 11:02:12 Seeking Alpha
Cardiovascular Systems press release (CSII): Q2 GAAP EPS of -$0.23 misses by $0.09.Revenue of $59.1M (-7.9% Y/Y) misses by $3.56M.For the fiscal year ending June 30, 2022,